Skip to main content

HLI is proud to celebrate the success of Dr. Janice Leung and Dr. Scott Tebbutt, who along with their co-applicants and research teams, have received over $1.8 million in funding from the Canadian Institutes of Health Research (CIHR) Fall 2025 Project Grant competition. This funding will support important new research aimed at improving care for people living with lung disease, heart transplants, and health inequities across Canada.

 Understanding COPD Beyond Smoking

Dr. Janice Leung will lead the MAPLE-SEED Study, a project focused on understanding why some people develop chronic obstructive pulmonary disease (COPD) even though they have never smoked. COPD is a long-term lung disease that affects breathing and impacts more than 2.6 million Canadians.

While smoking is a major cause of COPD, it does not explain all cases. About one in five people with COPD have never smoked, suggesting other factors play an important role. Dr. Leung’s research looks at how life experiences and living conditions such as childhood hardship, income level, education, air pollution, diet, and neighbourhood environment can affect lung health over time.

The study focuses on changes in the body that occur at the molecular level, specifically through a process called DNA methylation. In simple terms, DNA methylation acts like a biological record of the experiences a person has had throughout their life. These changes can also reflect how quickly the body is aging, sometimes referred to as a “biological clock.”

Dr. Leung’s team hypothesizes that long-term exposure to social and environmental challenges speeds up biological aging and increases the risk of COPD and poor breathing outcomes.

Using information from two large Canadian studies that follow people over many years, the research will:

In the long term, the applicants hope that this work leads to the development of a simple blood test to help identify people at higher risk of worsening lung disease.

This research brings together experts from many fields, including lung medicine, public health, biology, and data science. The goal is to help prevent COPD, improve early detection, and reduce health disparities.

Improving Early Detection of Complications After Heart Transplantation

Dr. Scott Tebbutt’s research project focuses on improving care for people who have received a heart transplant. Over time, many transplant recipients develop a condition called cardiac allograft vasculopathy (CAV), which causes the blood vessels of the transplanted heart to narrow. CAV is the leading cause of late transplant failure.

Currently, CAV is usually detected through invasive heart tests, often only after symptoms appear. Dr. Tebbutt’s team aims to develop a simple blood test that can detect signs of CAV much earlier, before serious damage occurs.

The research will look for small changes in the blood such as proteins and molecules that signal early injury or inflammation in the heart. By studying blood samples collected at different times after transplantation, the team hopes to identify patterns that clearly separate healthy recovery from early disease.

This research project will:

Led by Dr. Tebbutt and Co-Applicant and HLI Research Associate Dr. Chengliang Yang, the long-term goal of this research is to improve monitoring, reduce invasive testing, and help patients receive treatment sooner.

Making Research Matter for Patients

Together, these CIHR-funded projects reflect HLI’s commitment to research that puts patients first. By studying how social conditions affect lung disease and by developing earlier, less invasive tests for heart transplant complications, these projects aim to improve quality of life, reduce health disparities, and support better outcomes for patients across Canada.

Congratulations to Dr. Leung, Dr. Tebbutt, and their research teams and co-applicants on being awarded these project grants.

On January 19, 2026, Zeren Sun, a PhD candidate working with Dr. Pascal Bernatchez, gave a talk as part of the ongoing Seminar Series at the Centre for Heart Lung Innovation (HLI). The presentation, titled “The Interplay Between Circulating Lipoproteins and Intramuscular Lipids in the Pathogenesis of Dysferlin-related Muscular Dystrophy,” explored the role cholesterol plays in muscular dystrophy (MD), a condition that causes progressive muscle weakness.

Zeren’s research focused on how imbalances in cholesterol levels, both in the blood and within muscle cells, could contribute to the worsening of MD. Healthy muscles depend on a proper cholesterol balance, something patients on cholesterol-lowering medications called statins know all too well, as they often cause statin-associated myopathies, such as muscle pain. But in people with MD, this balance is also disrupted, but differently. Zeren shared how disruptions in cholesterol can interfere with how muscles process fats, leading to muscle damage and reducing the ability of muscles to repair themselves, especially in the absence of a protein called dysferlin.

Using patient data, mouse models, and lab-grown muscle cells, the Bernatchez lab found that it is the presence of harmful “bad” cholesterol particles, the severity of MD is worsened. Their research also suggests that dysferlin might help control how cholesterol moves within muscle cells, which could lead to potential new treatment options. Additionally, certain dietary fats may help improve cholesterol balance in the muscles, offering a possible approach to managing MD. Zeren’s work emphasizes the importance of understanding how cholesterol affects muscle health and suggests that targeting cholesterol pathways might help improve treatment strategies for MD.

If you want to connect with Zeren and learn more about his work, feel free to visit his ResearchGate profile here: https://www.researchgate.net/profile/Zeren-Sun

Yejin Kang Explores the Link Between Cholesterol and Muscular Dystrophy

On January 12th, HLI  hosted another insightful session in our ongoing Seminar Series. This week, Yejin Kang, a Postdoctoral Fellow at Bernatchez Lab, shared her exciting research on how cholesterol affects muscle health, particularly in the context of muscular dystrophy.

Muscular dystrophy (MD) is a group of genetic conditions that cause muscle weakness and damage. Yejin’s talk, titled The Role of Circulating Cholesterol in Muscular Dystrophy and Muscle Regeneration, explored how changes in cholesterol levels can worsen the effects of this disease and even hinder the body’s ability to repair muscles.

One key takeaway from Yejin’s work is how statin intolerance, a condition that leads to muscle pain, can demonstrate how sensitive muscles are to fluctuations in cholesterol levels. Bernatchez’s lab has been studying the relationship between cholesterol and muscle dysfunction, using pre-clinical models and human samples to uncover new insights. In one experiment, they found that an unhealthy cholesterol level dramatically worsened the condition of mice with muscular dystrophy, leading to severe muscle wasting.

Yejin’s research doesn’t stop at understanding the problem. She is also working on finding better ways to prevent or treat this muscle degeneration by studying how different cholesterol levels impact muscle healing. The team is specifically looking at a group of mice with a genetic mutation similar to one seen in humans with muscular dystrophy, using them to test how cholesterol diets affect muscle regeneration after injury.

Her work is part of a larger effort to understand how metabolic factors like cholesterol can play a role in muscle diseases and could eventually lead to new treatment options.

The seminar was a wonderful opportunity to learn about the real-world impact of cholesterol on muscle health, and Yejin’s contributions to this important area of research are invaluable in the quest for better treatments for muscular dystrophy.

If you want to connect with Yejin and learn more about her work, feel free to visit her ResearchGate profile: https://www.researchgate.net/profile/Yejin-Kang

By Josie Tuong
Josie Tuong is a Master’s student in Dr. Koelwyn’s Lab. Her research focuses on how chronic exercise changes the trancriptomic profile (a type of genetic data) in monocytes (a type of innate immune cell) in aging mice.

Research Focus and Scientific Vision

What is the focus of your research?

What are the big questions that you want to answer?

What sets your research apart from others in our centre? And conversely, in what way do you think your work is/will be complementary to what is being done in the centre?


Training Background and Pathway to an Academic Career

Can you tell us about your training?

Was there a turning point in your career?

“Of course, there are hard days in everything, but for the last 15 years, I have woken up pretty much every day excited to do what I do.”

Was becoming a PI something you wanted from the start?


Words of Advice for Trainees

If you were to talk to someone about to enter grad school or start a postdoctoral position, what advice would you give them?

“I give this advice to all trainees: before starting something, whether it’s your master’s program, or especially a PhD program, do your homework.”

What should trainees look for in such opportunities?

Would you elaborate on the importance of finding a good supervisor?

“Think carefully about what interests you, what is interesting to other people, and find a good person who will care about your success to help you get where you want to go.”


Beyond the Lab

What do you do outside of research?

 

On November 12, 2025, HLI PIs Drs. Pat Camp and Graeme Koelwyn and Science and Grant Writers Drs. Kasia Adolphs and Evan Phillips participated in a Providence Research Trainee Collaborative Grant Writing Workshop.

During the session, moderated by PR Research Director Dr. Scott Tebbutt, panelists shared key strategies for writing fellowship and grant applications. Topics included the use of storytelling in grant writing, how best to align an application with funder priorities, balancing authenticity and strategic positioning, common pitfalls to avoid, handling rejection and re-submission, mentoring and leadership – and more.

Key Takeaways

✅ Tailor every application to the funder’s priorities and evaluation criteria.

✅ Use storytelling strategically to connect past experiences with future goals.

✅ Plan timelines early – avoid last-minute submissions.

✅ Engage authentically with EDI principles and community relationships.

✅ Seek feedback and mentorship to strengthen your application.

This event was part of a series of events organized by the Providence Research Trainee Collaborative to support trainees in successfully navigating their career paths. Following the panel discussion, trainees were encouraged to join a networking session, which provided the opportunity to explore and discuss topics further.

A big thank you to Kaylie Friess (Project Manager) and Josephine Jung (Director, Special Projects and Strategy) from Providence Research for organizing the event!

Story by Basak Ashley Sahin. Edited by Tiffany Chang.

From personal experience to advocacy

Leading by example

Creating space for others to thrive


Outside of the lab

Job Description:

A Research Associate (RA) position is available at the University of British Columbia (UBC), Division of Respiratory Medicine, Department of Medicine under the direction of Dr. Scott J. Tebbutt, Professor of Medicine of UBC Faculty of Medicine and Principal Investigator and Director of Education of Centre for Heart Lung Innovation at St Paul’s Hospital.

The RA will work with an interdisciplinary and international team to support the Immunophenotyping of a COVID-19 pneumonia Cohort (IMPACC) Study. The RA and Dr. Tebbutt’s team members will identify molecular endotypes of long-COVID-19 (also called Post COVID-19 Syndrome) during and after COVID-19 infection, in peripheral blood, plasma, nasal swabs, and airway tissue samples, by carrying out unsupervised analysis of multi-omics profiles at a single time-point or considering the time-course profile during infection. Dr. Tebbutt’s team aims to characterize the molecular heterogeneity during COVID-19 infection and to develop biomarkers of prognostic significance as they relate to the development of long-COVID-19. The distinct molecular patterns associated with each endotype may, in turn, help elucidate novel mechanisms of action and inform drug discovery and repurposing efforts.

The RA will play a critical role in the project team, providing scientific and pulmonology-based expertise to support hypothesis generation, planning, coordination, and identification of host molecular endotypes associated with diverse COVID-19 outcomes and new variants in a longitudinal multi-omics cohort study of 1000 patients. The RA will be responsible for several domains, including, but not limited to: project coordination, critical evaluation of clinical data, applications for funding, communication with collaborators and stakeholders, The RA will provide additional support to the Principal Investigator and collaborators as needed. The COVID-19 pandemic has created a climate of rapidly evolving information, goals and questions, and the RA will be expected to respond quickly and adapt to changing demands and short timelines.

Responsibilities will include, but will not be limited to:

Requirements:

Duration and salary:

The position will begin March 1, 2026 for a period of 1 year with the possibility of extension.

Salary is $76,128.00 per annum plus benefits.

Application:

The deadline for interested individuals is December 10, 2025. Applicants should send a cover letter and curriculum vitae to Dr. Tebbutt: scott.tebbutt@hli.ubc.ca

Equity and diversity are essential to academic excellence. An open and diverse community fosters the inclusion of voices that have been underrepresented or discouraged. We encourage applications from members of groups that have been marginalized on any grounds enumerated under the B.C. Human Rights Code, including sex, sexual orientation, gender identity or expression, racialization, disability, political belief, religion, marital or family status, age, and/or status as a First Nation, Metis, Inuit, or Indigenous person.

All qualified candidates are encouraged to apply; however, Canadians and permanent residents will be given priority.

By Gurpreet Singhera
Gurpreet Singhera is the Bruce McManus Cardiovascular Biobank Manager.
An early picture of me in 2002 (blue arrow) with my HLI family.
Processing a patient’s donated explanted heart for biobanking.
Introducing an attentive group of High School students to biomedical research.